IBA announces its partnership with Beckman Coulter for the distribution of IBA's Streptamer product portfolio

05-May-2010 - Germany

IBA GmbH and Beckman Coulter, Inc. have agreed to a partnership for the distribution of IBA's Streptamer® products. With this partnership, IBA provides Beckman Coulter with exclusive distribution rights for IBA´s proprietary Streptamer technology in North America and co-exclusive distribution rights outside of North America. In co-exclusive regions, IBA will continue to market the Streptamer technology via direct sales, offer custom services and provide technical support.

“We are very pleased that we have found Beckman Coulter as an ideal partner with a strong global reputation in cell sciences for selling our Streptamer products to customers in North America,” said Lothar Germeroth, CEO of IBA GmbH. “We believe that the expansion to the North American market through the experienced sales and marketing team of Beckman Coulter will strongly enhance the visibility of our Streptamer technology as a platform for unique immunological research applications.”

Streptamer technology allows for antigen-specific staining and isolation of naturally occurring T-cells with reversible reagents that do not impact cell expression, trigger activation or induce functional changes. Since all reagents used for staining or isolation can be removed with biotin, the isolated T-cells remain uncompromised and retain phenotypic and functional characteristics undistinguishable from naturally occurring cells.

“The addition of the Streptamer technology to Beckman Coulter´s tetramer product lines will open up new possibilities for researchers to study cells in their natural state and under native conditions,“ said Brad Calvin, vice president of Beckman Coulter´s Flow Cytometry Business Center. “This makes the Streptamer technology a valuable tool for immunological research and could facilitate the discovery of novel therapeutic approaches.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances